fda compounding peptides bpc 157 warning letter issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of FDA Pharmacy Compounding Committee Votes
Description
What they found: Oral AOD-9604 reduced body fat by 18 to 22 % vs placebo, comparable to injection administration No changes in total body weight (because lean mass rose slightly) Decrease in plasma triglycerides by 30 % Decrease in resting free fatty acids (paradoxically, mobilization of fat from depots into oxidation) No GI side effects Why it matters: It suggested that AOD-9604 could work orally , a rare property for a peptide
Neuroscience Letters, 675(1), 96101

Experience premium mobile IV therapy in Yorba Linda that helps you recover and rejuvenate without ever leaving your location

This can increase anemia risk
